Opinion|Videos|March 28, 2024
The Study Design and Early Findings from the INTERCEPT Study in CRC
An overview of the rationale and study design of the INTERCEPT study in patients with colorectal cancer, with a focus on the early key findings.
Advertisement
Episodes in this series
Advertisement
Related to this article
More than two-thirds of patients with mismatch repair–deficient locally advanced rectal cancer achieved a clinical complete response with dostarlimab alone.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
2
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
3
Pembrolizumab Plus Chemo Improves PFS in PD-L1+ HR+/HER2– Breast Cancer
4
CEA-High Expression Shows Early Promise as a Biomarker for BG-C477 in NSCLC
5